Andrew Huberman· PhD
Psychedelics/SSRIs as Plasticity Tools, SSRIs & Bone Strength, Failed Clinical Trials (2:13:18)
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Psychedelics/SSRIs as Plasticity Tools, SSRIs & Bone Strength, Failed Clinical Trials (2:13:18)
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
what we're really trying to do whether or not it's transrenal magnetic stimulation or now we can throw ketamine in there or psilocybin or ssris we're that treating depression is about rewiring the brain
all of them Target specific neuromodulator systems in the brain and body and at the same time it's fairly clear that mood disorders such as major depression are not necessarily deficits in things like serotonin or dopamine they can be but most often they are not so why are such drugs prescribed for mood disorders and for mental health disorders well because if specific neuromodulators like serotonin dopamine or epinephrine are dramatically increased above Baseline that affords the brain the ability to rewire itself really the way to think about ssris or atypical anti-depressants or psilocybin for the treatment of major depression is really to think about them as chemical tools to open or access neuroplasticity
Um talk therapy, SSRIs, and other prescription anti-depressants, psilocybin, and any psychedelic for the treatment of depression and on and on all funnel into brain plasticity.
But whether it's SSRIs or psilocybin, they're both just tools for plasticity that drive serotonin.